Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
NCT03102320Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2017
- Primary completion
- Sep 2020
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 12
01
Overview
Phase 1, open-label trial of anetumab ravtansine in cholangiocarcinoma (CCA), pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 3 more (3 arms), sponsored by Bayer. Primary endpoints: Dose Limiting Toxicities at 3 weeks, Objective Response Rate at 26 months and 1 more. Started May 2017; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
cholangiocarcinoma (CCA)pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)triple negative breast cancer (TNBC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03102320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102320.